Global Epidemiology of Hepatocellular Carcinoma: An Emphasis on Demographic and Regional Variability

Clinics in Liver Disease

Volumn 19, Issue 2, 2015, Pages 223-238

  McGlynn, Katherine A ^a   Petrick, Jessica L ^a   London, W Thomas ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Aflatoxin; Alcohol; Chemoprevention; Coffee; Diabetes; Hepatitis B virus; Hepatitis C virus; Incidence

Indexed keywords

ACETYLSALICYLIC ACID; AFLATOXIN; ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AFRICA; ALCOHOL CONSUMPTION; ASIA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COFFEE; DIABETES MELLITUS; ETHNIC DIFFERENCE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; METABOLIC SYNDROME X; OBESITY; REVIEW; SEX DIFFERENCE; SEX RATIO; SMOKING; TEA; CARCINOMA, HEPATOCELLULAR; EPIDEMIOLOGY; ETHNOLOGY; EUROPE; HEALTH; INCIDENCE; LIVER NEOPLASMS; MORTALITY; NORTH AMERICA; PACIFIC ISLANDS; RISK FACTOR; SOUTH AMERICA;

AFRICA; ASIA; CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; EUROPE; GLOBAL HEALTH; HUMANS; INCIDENCE; LIVER NEOPLASMS; NORTH AMERICA; OCEANIA; RISK FACTORS; SOUTH AMERICA;

EID: 84928825539     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2015.01.001     Document Type: Review

References (116)

1. Ferlay J, Parkin DM, Curado MP, et al. Cancer incidence in five continents, volumes I to X: IARC CANCERBase No. 10 [Internet]. 2014. Available at: . Accessed November 25, 2014. http://ci5.iarc.fr.
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon (France): International Agency for Research on Cancer. 2013. Available at: . Accessed November 12, 2014. http://globocan.iarc.fr.
3. Altekruse S.F., Henley S.J., Cucinelli J.E., et al. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014, 109(4):542-553.
4. Gao S., Yang W.S., Bray F., et al. Declining rates of hepatocellular carcinoma in urban Shanghai: incidence trends in 1976-2005. Eur J Epidemiol 2012, 27(1):39-46.
5. Tanaka H., Imai Y., Hiramatsu N., et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008, 148(11):820-826.
6. Surveillance, Epidemiology, and End Results (SEER) Program () SEER*Stat Database: Incidence - SEER 18 Regs Research Data+ Hurricane Katrina Impacted Louisiana Cases, Nov 2013 Sub (1973-2011) Total U.S., National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, based on the November 2013 submission. 2014. http://www.seer.cancer.gov.
7. Surveillance, Epidemiology and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence-CiNA Analytic File, 1995-2009. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch. 2012.
8. Perz J.F., Armstrong G.L., Farrington L.A., et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. JHepatol 2006, 45(4):529-538.
9. Paraskevis D., Magiorkinis G., Magiorkinis E., et al. Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology 2013, 57(3):908-916.
10. Simmonds P. Reconstructing the origins of human hepatitis viruses. Philos Trans R Soc Lond B Biol Sci 2001, 356(1411):1013-1026.
11. International Agency for Research on Cancer Hepatitis viruses 1994, International Agency for Research on Cancer, Lyon (France).
12. Ott J.J., Stevens G.A., Groeger J., et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012, 30(12):2212-2219.
13. Centers for Disease Control and Prevention. Hepatitis B. 2010. Available at: . Accessed November 5, 2014. http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/hepatitis-b.aspx.
14. Marinier E., Barrois V., Larouze B., et al. Lack of perinatal transmission of hepatitis B virus infection in Senegal, West Africa. JPediatr 1985, 106(5):843-849.
15. Ming L., Thorgeirsson S.S., Gail M.H., et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002, 36(5):1214-1220.
16. Chen G., Lin W., Shen F., et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006, 101(8):1797-1803.
17. Chen C.J., Yang H.I., Iloeje U.H. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009, 49(Suppl 5):S72-S84.
18. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49(Suppl 5):S45-S55.
19. McMahon B.J. Natural history of chronic hepatitis B. Clin Liver Dis 2010, 14(3):381-396.
20. Sumi H., Yokosuka O., Seki N., et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003, 37(1):19-26.
21. World Health Organization. Hepatitis B. 2010. Available at: . Accessed November 3, 2014. http://www.who.int/immunization/topics/hepatits_b/en/index.html.
22. Goldstein S.T., Zhou F., Hadler S.C., et al. Amathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34(6):1329-1339.
23. World Health Organization Fact sheet no. 204, Hepatitis B 2014, World Health Organization, Available at:, Accessed December 3, 2014. http://www.who.int/mediacentre/factsheets/fs204/en/.
24. Filippelli M., Lionetti E., Gennaro A., et al. Hepatitis B vaccine by intradermal route in non responder patients: an update. World J Gastroenterol 2014, 20(30):10383-10394.
25. Chang M.H., You S.L., Chen C.J., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. JNatl Cancer Inst 2009, 101(19):1348-1355.
26. Chiang C.J., Yang Y.W., You S.L., et al. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013, 310(9):974-976.
27. Liang X., Bi S., Yang W., et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. JInfect Dis 2009, 200(1):39-47.
28. Ang L.W., Cutter J., James L., et al. Seroepidemiology of hepatitis B virus infection among adults in Singapore: a 12-year review. Vaccine 2013, 32(1):103-110.
29. Yan H., Peng B., Liu Y., et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. JVirol 2014, 88(6):3273-3284.
30. Ding S., Robek M.D. Cytidine deamination and cccDNA degradation: a new approach for curing HBV?. Hepatology 2014, 60(6):2118-2121.
31. Choo Q.L., Kuo G., Weiner A.J., et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244(4902):359-362.
32. Simmonds P. Genetic diversity and evolution of hepatitis C virus: 15 years on. JGen Virol 2004, 85(Pt 11):3173-3188.
33. Simmonds P., Holmes E.C., Cha T.A., et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. JGen Virol 1993, 74(Pt 11):2391-2399.
34. Pybus O.G., Barnes E., Taggart R., et al. Genetic history of hepatitis C virus in East Asia. JVirol 2009, 83(2):1071-1082.
35. Pybus O.G., Markov P.V., Wu A., et al. Investigating the endemic transmission of the hepatitis C virus. Int J Parasitol 2007, 37(8-9):839-849.
36. Bostan N., Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol 2010, 36(2):91-133.
37. Tanaka Y., Hanada K., Mizokami M., et al. Inaugural Article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002, 99(24):15584-15589.
38. Iida F., Iida R., Kamijo H., et al. Chronic Japanese schistosomiasis and hepatocellular carcinoma: ten years of follow-up in Yamanashi Prefecture, Japan. Bull World Health Organ 1999, 77(7):573-581.
39. Frank C., Mohamed M.K., Strickland G.T., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355(9207):887-891.
40. Armstrong G.L., Alter M.J., McQuillan G.M., et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000, 31(3):777-782.
41. Salomon J.A., Weinstein M.C., Hammitt J.K., et al. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002, 156(8):761-773.
42. Seeff L.B., Miller R.N., Rabkin C.S., et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000, 132(2):105-111.
43. Davis G.L., Alter M.J., El-Serag H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138(2):513-521. 521.e1-6.
44. Sofia M.J., Bao D., Chang W., et al. Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. JMed Chem 2010, 53(19):7202-7218.
45. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. NEngl J Med 2014, 370(3):211-221.
46. IARC Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. Supplement 7 1987, International Agency for Research on Cancer, Lyon (France).
47. Wild C.P., Hall A.J. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000, 462(2-3):381-393.
48. Plymoth A., Viviani S., Hainaut P. Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett 2009, 286(1):15-21.
49. Sun C.A., Wu D.M., Wang L.Y., et al. Determinants of formation of aflatoxin-albumin adducts: a seven-township study in Taiwan. Br J Cancer 2002, 87(9):966-970.
50. Qian G.S., Ross R.K., Yu M.C., et al. Afollow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994, 3(1):3-10.
51. Ross R.K., Yuan J.M., Yu M.C., et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992, 339(8799):943-946.
52. Kuang S.Y., Lekawanvijit S., Maneekarn N., et al. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev 2005, 14(2):380-384.
53. Liu Y., Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 2010, 118(6):818-824.
54. Wild C.P., Gong Y.Y. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 2010, 31(1):71-82.
55. Chen J.G., Egner P.A., Ng D., et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila) 2013, 6(10):1038-1045.
56. London W.T., McGlynn K.A. Liver Cancer. Cancer epidemiology and prevention 2006, 763-786. Oxford University Press, New York. D. Schottenfeld, J.F. Fraumeni (Eds.).
57. Donato F., Tagger A., Gelatti U., et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002, 155(4):323-331.
58. Kuper H., Tzonou A., Kaklamani E., et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000, 85(4):498-502.
59. Yuan J.M., Govindarajan S., Arakawa K., et al. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 2004, 101(5):1009-1017.
60. International Agency for Research on Cancer Alcohol drinking 1988, International Agency for Research on Cancer, Lyon (France).
61. World Cancer Research Fund/American Institute for Cancer Research Food, nutrition, physical activity, and the prevention of cancer: a global perspective 2007, American Institute for Cancer Research, Washington, DC.
62. Turati F., Galeone C., Rota M., et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol 2014, 25(8):1526-1535.
63. Alcorn T. Mongolia's struggle with liver cancer. Lancet 2011, 377(9772):1139-1140.
64. Chen J., Han Y., Xu C., et al. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies. Eur J Cancer Prev 2015, 24:89-99.
65. El-Serag H.B., Richardson P.A., Everhart J.E. The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. Am J Gastroenterol 2001, 96(8):2462-2467.
66. Wang C., Wang X., Gong G., et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012, 130(7):1639-1648.
67. Wang P., Kang D., Cao W., et al. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012, 28(2):109-122.
68. Saunders D., Seidel D., Allison M., et al. Systematic review: the association between obesity and hepatocellular carcinoma: epidemiological evidence. Aliment Pharmacol Ther 2010, 31(10):1051-1063.
69. Larsson S.C., Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007, 97(7):1005-1008.
70. Jinjuvadia R., Patel S., Liangpunsakul S. The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. JClin Gastroenterol 2014, 48(2):172-177.
71. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87(1):4-14.
72. James W.P. The epidemiology of obesity: the size of the problem. JIntern Med 2008, 263(4):336-352.
73. IARC Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004, 83:1-1438.
74. The health consequences of smoking: 50 years of progress. A report of the Surgeon General. Available at: . Accessed December 10, 2014. http://www.surgeongeneral.gov/library/reports/50-years-of-progress/.
75. Lee Y.C., Cohet C., Yang Y.C., et al. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol 2009, 38(6):1497-1511.
76. Bravi F., Bosetti C., Tavani A., et al. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013, 11(11):1413-1421.e1.
77. Fon Sing M., Yang W.S., Gao S., et al. Epidemiological studies of the association between tea drinking and primary liver cancer: a meta-analysis. Eur J Cancer Prev 2011, 20(3):157-165.
78. Bamia C., Lagiou P., Jenab M., et al. Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer 2014, 10.1002/ijc.29214.
79. Setiawan V.W., Wilkens L.R., Lu S.C., et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2014, 148(1):118-125.
80. Cavin C., Holzhaeuser D., Scharf G., et al. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol 2002, 40(8):1155-1163.
81. Muriel P., Arauz J. Coffee and liver diseases. Fitoterapia 2010, 81(5):297-305.
82. Boettler U., Sommerfeld K., Volz N., et al. Coffee constituents as modulators of Nrf2 nuclear translocation and ARE (EpRE)-dependent gene expression. JNutr Biochem 2011, 22(5):426-440.
83. Ludwig I.A., Clifford M.N., Lean M.E., et al. Coffee: biochemistry and potential impact on health. Food Funct 2014, 5(8):1695-1717.
84. Yang C.S., Wang X., Lu G., et al. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009, 9(6):429-439.
85. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-1681.
86. Chan K.K., Oza A.M., Siu L.L. The statins as anticancer agents. Clin Cancer Res 2003, 9(1):10-19.
87. Gazzerro P., Proto M.C., Gangemi G., et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 2012, 64(1):102-146.
88. Chiu H.F., Ho S.C., Chen C.C., et al. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol 2011, 106(5):894-898.
89. Lai S.W., Liao K.F., Lai H.C., et al. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol 2013, 28(6):485-492.
90. Leung H.W., Chan A.L., Lo D., et al. Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opin Drug Saf 2013, 12(1):19-27.
91. Tsan Y.T., Lee C.H., Ho W.C., et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. JClin Oncol 2013, 31(12):1514-1521.
92. Tsan Y.T., Lee C.H., Wang J.D., et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. JClin Oncol 2012, 30(6):623-630.
93. Friis S., Poulsen A.H., Johnsen S.P., et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005, 114(4):643-647.
94. Marelli C., Gunnarsson C., Ross S., et al. Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. JAm Coll Cardiol 2011, 58(5):530-537.
95. El-Serag H.B., Johnson M.L., Hachem C., et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009, 136(5):1601-1608.
96. Khurana V., Saluja A., Caldito G., et al. Statins are protective against hepatocellular cancer in patients with hepatitis C virus infection: half a million U.S. veterans' study. Gastroenterology 2005, 128:A714.
97. Friedman G.D., Flick E.D., Udaltsova N., et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008, 17(1):27-36.
98. McGlynn K.A., Divine G.W., Sahasrabuddhe V.V., et al. Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiol 2014, 38(5):523-527.
99. Bjorkhem-Bergman L., Backheden M., Soderberg Lofdal K. Statin treatment reduces the risk of hepatocellular carcinoma but not colon cancer-results from a nationwide case-control study in Sweden. Pharmacoepidemiol Drug Saf 2014, 23(10):1101-1106.
100. Pradelli D., Soranna D., Scotti L., et al. Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev 2012, 22(3):229-234.
101. Singh S., Singh P.P., Singh A.G., et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013, 144(2):323-332.
102. Franciosi M., Lucisano G., Lapice E., et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS one 2013, 8(8):e71583.
103. Singh S., Singh P.P., Singh A.G., et al. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol 2013, 108(4):510-519. [quiz: 520].
104. Zhang H., Gao C., Fang L., et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 2013, 48(1):78-87.
105. Hagberg K.W., McGlynn K.A., Sahasrabuddhe V.V., et al. Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes. Br J Cancer 2014, 111(9):1710-1717.
106. Conaghan P.G. Aturbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int 2012, 32(6):1491-1502.
107. Cervello M., Foderaa D., Florena A.M., et al. Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol 2005, 11(30):4638-4643.
108. Fodera D., D'Alessandro N., Cusimano A., et al. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci 2004, 1028:440-449.
109. Leng J., Han C., Demetris A.J., et al. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003, 38(3):756-768.
110. Cibere J., Sibley J., Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997, 40(9):1580-1586.
111. Coogan P.F., Rosenberg L., Palmer J.R., et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000, 9(1):119-123.
112. Sahasrabuddhe V.V., Gunja M.Z., Graubard B.I., et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. JNatl Cancer Inst 2012, 104(23):1808-1814.
113. Knights K.M., Mangoni A.A., Miners J.O. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol 2010, 3(6):769-776.
114. Jankowska H., Hooper P., Jankowski J.A. Aspirin chemoprevention of gastrointestinal cancer in the next decade. a review of the evidence. Pol Arch Med Wewn 2010, 120(10):407-412.
115. Kern M.A., Schubert D., Sahi D., et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002, 36(4 Pt 1):885-894.
116. Imaeda A.B., Watanabe A., Sohail M.A., et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. JClin Invest 2009, 119(2):305-314.